ChromoGenics AB reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 4.39 million compared to SEK 3.5 million a year ago. Revenue was SEK 6.32 million compared to SEK 3.28 million a year ago. Net loss was SEK 11.86 million compared to SEK 15.57 million a year ago. Basic loss per share from continuing operations was SEK 7 compared to SEK 90 a year ago. Diluted loss per share from continuing operations was SEK 7 compared to SEK 90 a year ago.
For the six months, sales was SEK 10.78 million compared to SEK 12.66 million a year ago. Revenue was SEK 13.07 million compared to SEK 12.55 million a year ago. Net loss was SEK 24.95 million compared to SEK 33.17 million a year ago. Basic loss per share from continuing operations was SEK 10 compared to SEK 195 a year ago. Diluted loss per share from continuing operations was SEK 10.